Maximus advertises sermorelin injections starting at $199.99 per month, alongside daily-cost messages and an at-home kit. The program is presented within a wider performance and hormone-health offering. A useful review starts with the actual monthly plan and the clinical reasons for considering it.

This Second Look review examines the public offer and the full financial commitment. CoreAge Rx is this publication’s featured commercial partner and appears first in our shortlists. That placement does not establish that another provider is clinically inferior. We reviewed public material; we have not purchased treatment, audited the pharmacy, or collected comparable patient outcome data.

Keep this in mind

Maximus may be relevant to readers comparing an at-home program with a stated monthly starting price. The key questions concern billing consistency, individualized evaluation, and follow-up rather than performance language alone.

Reconciling daily messaging with a monthly commitment

The reviewed page contains more than one daily-cost statement. Rather than choosing whichever conversion looks most attractive, we use the explicit monthly starting figure and recommend confirming the actual checkout total. Ask whether a longer commitment, selected quantity, or promotional offer changes the charge and when future payments are collected. The provider's own page is the source of the advertised terms recorded here, checked September 21, 2026. Offers can change after that date.

Published offer: From $199.99/month. Published monthly starting rate; the page also uses daily figures that need reconciliation. Use our cost guide to distinguish an introductory figure from an ongoing commitment. A promotional starting price should never stand in for the complete amount you authorize.

What the service description tells us

Maximus states that laboratory testing is not required to qualify for its sermorelin program. This is a provider's entry policy, not a conclusion that testing would never be appropriate for a particular person. If symptoms suggest pituitary disease or another medical problem, ask whether further evaluation is needed before making a treatment decision. The public description gives a starting point for questions; it does not establish a measured standard of care. State availability, clinician eligibility decisions, pharmacy assignment, and the final prescription should be confirmed for your own situation.

A useful review follows responsibility through the whole process. Ask for the prescribing practice's name, the clinician responsible for follow-up, and the dispensing pharmacy's contact details. The pharmacy checklist explains why those organizations may be different from the name on the website.

The claim that deserves a second look

The page describes potential benefits and also makes broad claims about suitability and safety. We have not measured patient outcomes or independently validated those claims. A history of cancer, a complex endocrine condition, or other hormone treatment deserves an individualized discussion, potentially involving an existing specialist. The Endocrine Society's guidance on adult growth hormone deficiency concerns a defined diagnosis. It should not be taken as an endorsement of sermorelin for every person experiencing normal aging.

Our benefits and evidence guide separates studies of the exact drug from research about a related hormone pathway. Ask which findings apply to the proposed formulation and your intended outcome. A laboratory change and a meaningful improvement in everyday life are different claims.

A conversation to have before paying

Start with this provider-specific question: How is the $199.99 monthly starting rate billed, and what clinical monitoring is appropriate even if entry does not require labs? Request the answer in writing along with the selected product, the first charge, and the renewal date. If a detail is not available on the sales page, treat it as unresolved rather than assuming it is included or free.

Then discuss why treatment is being considered. Describe the problem in practical terms, such as when tiredness occurs or how sleep has changed, and provide your complete health history. Our consultation questions cover alternatives, monitoring, and what happens when a clinician decides not to prescribe.

Safety, pharmacy, and follow-up

Compounded sermorelin is not FDA-approved. The FDA explains that compounded preparations do not undergo its premarket review for safety, effectiveness, and quality. That distinction applies to Maximus and to our featured partner alike.

Discuss allergies, tumor or cancer history, pituitary or other endocrine conditions, glucose concerns, pregnancy or breastfeeding where relevant, and all medicines and supplements. The side-effect guide provides general context, but the prescriber must assess your circumstances. Severe reactions such as difficulty breathing or face or throat swelling require emergency care.

If a prescription is issued, ask the pharmacist to reconcile the concentration, prescribed amount, supplied device, storage directions, and beyond-use date. Never copy another person's syringe markings. Ask how to obtain help with a damaged or delayed shipment and which medical contact is available after the initial visit.

Who may find this option worth investigating

Maximus may be relevant to readers comparing an at-home program with a stated monthly starting price. The key questions concern billing consistency, individualized evaluation, and follow-up rather than performance language alone. We would pause the purchasing decision if the exact preparation, medical follow-up, or recurring bill remained unclear. Those are answerable questions, not reasons to substitute an unsupported star rating.

Before making a shortlist, compare the other reviewed services and the online-provider comparison. Keep a copy of the offer and the answers you received. A sound decision can end with a different service, further evaluation, or no treatment; the point is to understand the choice before making the commitment.

The source notes

Sources & further reading

Provider pages document advertised offers, not independently proven outcomes. Historical references may concern different products or uses. Sources were checked for this edition on September 21, 2026; offers can change.

  1. Maximus: reviewed product or program page
  2. Endocrine Society: Adult growth hormone deficiency guideline
  3. FDA: Compounding and FDA questions and answers